Incorporando los inhibidores de CDK 4/6 a la práctica Clínica habitual

14 / 38

First-line CDK inhibitors Study Designs
• HR+, HER2- ABC
• Postmenopausal
• Noprior systemic therapy in
this setting
• If neoadjuvant or adjuvant ET
administered, a disease free
interval of >12 months since
completion of ET
• ECOG PS ≤1
abemaciclib: 150 mg BID
Abemaciclib
plus
AI
Randomization
2 :1
placebo
plus
AI
N=493
abemaciclib: 150 mg BID
Palbociclib
plus
AI
Randomization
2 :1
placebo
plus
AI
N=666
abemaciclib: 150 mg BID
Ribociclib
plus
AI
Randomization
1 :1
placebo
plus
AI
N=668
PALOMA-2 1
MONALEESA-22
MONARCH-33
Primary endpoint:
Investigator-assessed PFS
1Finn RS, et al. N Engl J Med 2016; 2Hortobagyi G, et al. N Engl J Med 2016; 3di Leo A, et al. J Clin Oncol 2017